Biochim Biophys Acta 1863:24222435
In turn, use of these medications has skyrocketed
Studies show: Average ~15% body-weight reduction at ~68 weeks , with ~1 in 3 people reaching 20% loss (paired with diet and exercise)
It may be administered safely for longer periods, as well
For example, in the lungs, GLP-1s may reduce the inflammatory response, improve oxidative stress, regulate protease/anti-protease imbalance, improve airway mucus homeostasis and reduce airway remodeling to provide benefit in patients with COPD
[17] [18] This is a recognised caution for GLP-1 receptor agonist therapies (see semaglutide and tirzepatide UK SmPCs) and is likely relevant to retatrutide